Igor Astsaturov MD, PhD

Request an Appointment Online - Click Here New patients can request an appointment online or call

Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111-2497

Video: Igor Astsaturov MD, PhD

Igor Astsaturov MD, PhD

Colorectal Cancer Treatment at Fox Chase Cancer Center

GI Service Line

Learn about colorectal cancer treatment at Fox Chase Cancer Center. From diagnosis to treatment to concerns about your family, our team has experience than can help. (9 min.)

Patient Stories from Fox Chase Patients Dr. Astsaturov's
Patient Stories

  • Barry Dixon - Neuroendocrine Carcinoma Patient Stories
Dr. Igor Astsaturov


Assistant Professor

Meet other members of the
gastrointestinal cancer treatment team.

Clinical Expertise:

Gastrointestinal cancers including Pancreatic Cancer, Colorectal Cancer, and Liver Cancer


American Board of Internal Medicine;
Medical Oncology

Medical Education

I.M. Sechenov Medical Academy, Moscow, Russia, 1992


Internship and Residency in Internal Medicine, Good Samaritan Hospital, Baltimore, MD, 2002-2005;
PhD in Hematology/Oncology, Russian Hematological Research Center, Moscow, Russia, 1994-1996;
Residency in Internal Medicine/Hematology, Russian Hematological Research Center, Moscow, Russia, 1992-1994


Medical Oncology Fellow,
Fox Chase Cancer Center,
Postdoctoral Research Fellow,
Dept. of Immunology, Univ. of Toronto,
Ontario, Canada, 1998-2002

Honors and Awards

Research Training Award,
The Hospital for Sick Children, Toronto, Canada, 2000-2001;
G. Soros International Science Educational Program Award, Moscow, Russia, 1996-1997;
Training Award (ICRETT),
International Union Against Cancer, Geneva, Switzerland, 1995;
Physician's Diploma with Honors; Personal Lenin Scholarship for Academic Excellence;
Faculty of Medicine, Sechenov Medical Academy, Moscow, Russia, 1985-1992

Research Interests

Innovative drug therapy concepts based on the rational drug combinations and synthetic lethality; application of genomic medicine to cancer care.

Molecular Therapeutics Program

Cancer Metabolism and signaling

  • The central role for sterol metabolism in regulation of cell growth and signaling.
  • Pancreatic cancer biology and "smart drugs" for treatment of pancreatic cancer.
  • Translating therapeutic concepts to the clinic using the platform of patient-derived avatar models and genetically engineered pancreatic cancer models.



Dr. Astsaturov on My NCBI

  1.  Gabitova L, Restifo D, Gorin A, Manocha K, Handorf E, Yang DH, Cai KQ,
    Klein-Szanto AJ, Cunningham D, Kratz LE, Herman GE, Golemis EA, Astsaturov I.
    Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via
    LXR. Cell Rep. 2015 Sep 22;12(11):1927-38. doi: 10.1016/j.celrep.2015.08.023.
    Epub 2015 Sep 3. PubMed PMID: 26344763; PubMed Central PMCID: PMC4581991.
  2. Beeharry N, Banina E, Hittle J, Skobeleva N, Khazak V, Deacon S, Andrake M,
    Egleston BL, Peterson JR, Astsaturov I, Yen TJ. Re-purposing clinical kinase
    inhibitors to enhance chemosensitivity by overriding checkpoints. Cell Cycle.
    2014;13(14):2172-91. doi: 10.4161/cc.29214. Epub 2014 Jun 23. PubMed PMID:
    24955955; PubMed Central PMCID: PMC4111673.
  3. Perkins J, Boland P, Cohen SJ, Olszanski AJ, Zhou Y, Engstrom P, Astsaturov I.
    Successful imatinib therapy for neuroendocrine carcinoma with activating Kit
    mutation: a case study. J Natl Compr Canc Netw. 2014 Jun;12(6):847-52. PubMed
    PMID: 24925195; PubMed Central PMCID: PMC4112647.
  4. Gabitova L, Gorin A, Astsaturov I. Molecular pathways: sterols and receptor
    signaling in cancer. Clin Cancer Res. 2014 Jan 1;20(1):28-34. doi:
    10.1158/1078-0432.CCR-13-0122. Epub 2013 Oct 24. Review. PubMed PMID: 24158702;
    PubMed Central PMCID: PMC3859141.
  5. Liu H, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov I, Litwin
    S, Martin LP, Proia DA, Golemis EA, Connolly DC. Network analysis identifies an
    HSP90-central hub susceptible in ovarian cancer. Clin Cancer Res. 2013 Sep
    15;19(18):5053-67. doi: 10.1158/1078-0432.CCR-13-1115. Epub 2013 Jul 30. PubMed
    PMID: 23900136; PubMed Central PMCID: PMC3778161.
  6. Bagnyukova TV, Restifo D, Beeharry N, Gabitova L, Li T, Serebriiskii IG,
    Golemis EA, Astsaturov I. DUSP6 regulates drug sensitivity by modulating DNA
    damage response. Br J Cancer. 2013 Aug 20;109(4):1063-71. doi:
    10.1038/bjc.2013.353. Epub 2013 Jul 9. PubMed PMID: 23839489; PubMed Central
    PMCID: PMC3749559.
  7. Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D,
    Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y,
    Yang DH, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner
    LM, Herman GE, Golemis EA, Astsaturov I. Targeting C4-demethylating genes in the
    cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via
    increased EGF receptor degradation. Cancer Discov. 2013 Jan;3(1):96-111. doi:
    10.1158/2159-8290.CD-12-0031. Epub 2012 Nov 2. PubMed PMID: 23125191; PubMed
    Central PMCID: PMC3546138.
  8. Gorin A, Gabitova L, Astsaturov I. Regulation of cholesterol biosynthesis and
    cancer signaling. Curr Opin Pharmacol. 2012 Dec;12(6):710-6. doi:
    10.1016/j.coph.2012.06.011. Epub 2012 Jul 21. Review. PubMed PMID: 22824431;
    PubMed Central PMCID: PMC3504641.
  9. Dotan E, Meropol NJ, Zhu F, Zambito F, Bove B, Cai KQ, Godwin AK, Golemis EA,
    Astsaturov I, Cohen SJ. Relationship of increased aurora kinase A gene copy
    number, prognosis and response to chemotherapy in patients with metastatic
    colorectal cancer. Br J Cancer. 2012 Feb 14;106(4):748-55. doi:
    10.1038/bjc.2011.587. Epub 2012 Jan 12. PubMed PMID: 22240781; PubMed Central
    PMCID: PMC3322945.
  10. Bagnyukova TV, Serebriiskii IG, Zhou Y, Hopper-Borge EA, Golemis EA,
    Astsaturov I. Chemotherapy and signaling: How can targeted therapies supercharge
    cytotoxic agents? Cancer Biol Ther. 2010 Nov 1;10(9):839-53. Epub 2010 Nov 1.
    Review. PubMed PMID: 20935499; PubMed Central PMCID: PMC3012138.
  11. Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y,
    Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE,
    Sharma C, Jablonski SA, Serebriiskii IG, Weiner LM, Golemis EA. Synthetic lethal
    screen of an EGFR-centered network to improve targeted therapies. Sci Signal.
    2010 Sep 21;3(140):ra67. doi: 10.1126/scisignal.2001083. PubMed PMID: 20858866;
    PubMed Central PMCID: PMC2950064.
  12. Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S,
    Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ. Phase II and coagulation cascade
    biomarker study of bevacizumab with or without docetaxel in patients with
    previously treated metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2011
    Feb;34(1):70-5. doi: 10.1097/COC.0b013e3181d2734a. PubMed PMID: 20458210; PubMed
    Central PMCID: PMC3030655.
  13. Astsaturov I, Cohen RB, Harari PM. Clinical application of EGFR inhibitors in
    head and neck squamous cell cancer. Cancer Treat Res. 2008;139:135-52. Review.
    PubMed PMID: 18236715.